Kirkland & Ellis represents Hong Kong-listed MicroPort Scientific Corporation (SEHK: 00853) in its proposed US$190 million acquisition of the Cardiac Rhythm Management (CRM) business of NASDAQ-listed LivaNova PLC (NASDAQ: LIVN). The CRM business develops, manufactures and markets products for the diagnosis, treatment and management of heart rhythm disorders and heart failures.  The transaction, which was announced on November 20, is expected to close in the second quarter of 2018.

The Kirkland team was led by Hong Kong corporate partners Gary Li, Pierre Arsenault and Joey Chau.